In my opinion I don't think so. RGS is not in strong enough position to be spending its own cash on R&D. It's model is more about licensing out their products and having their licensing partners stump up the cash for trials/R&D. staff costs will also appear high at times like these. Without the staff trying to get the deals done there would be no RGS, and I doubt that the staff would choose to work for free.
RGS Price at posting:
11.5¢ Sentiment: Buy Disclosure: Held
